Pondo termo ao acesso não autorizado aos recursos genéticos (quer dizer, biopirataria): acesso aberto limitado 12/06/2018 by Intellectual Property Watch Leave a Comment O “acesso aos recursos genéticos” e a “participação justa e equitativa dos benefícios provenientes de sua utilização” vêm aturdindo delegados e delegações das 13 Conferências das Partes da Convenção das Nações Unidas sobre Diversidade Biológica, que entrou em vigor no ano de 1993. A expressão entre aspas conhecida pela sigla em inglês “ABS” é o terceiro objetivo do Convênio e se encontra entrelaçada pelos dois primeiros objetivos que são a conservação e o uso sustentável. Apesar de 25 anos de esforços e de uma bioeconomia de quase um trilhão de dólares, são muito poucos os contratos celebrados. Desses poucos, os benefícios monetários são tão baixos que as partes contratantes relutam em revelá-los. A “Lei brasileira de ABS” de 2015, que entrou em vigor no dia 6 de novembro de 2017 permite, por exemplo, a obtenção de royalties sobre vendas líquidas tão baixos que isso implica a celebração de contratos pela bagatela de uma décima parte de um por cento. Citando as palavras de um jurista erudito, os Usuários pagam “uma miséria pela biodiversidade”.
IP, AI, Health Commitments Mere Footnotes In Quarrel Between G6 And Trump? 11/06/2018 by Monika Ermert for Intellectual Property Watch 1 Comment Leaders at the G7 Summit tried to mitigate tensions by taking on some US favourites in their final communiqué like “forced technology transfers,” a topic brought up only recently by the United States at the World Trade Organisation. Forced technology transfers, according to US diplomats, are licensing and administrative rules entertained by China to oblige foreign firms to share technology in exchange for gaining access to the Chinese market. They also had sought to agree on a vision for artificial intelligence, a range of health issues, and foreign cyber interference with elections.
TRIPS Council Debates IP Improving Lives, Competition Law To Increase Medicines Access 07/06/2018 by Catherine Saez, Intellectual Property Watch 1 Comment Whether intellectual property rights are improving lives or whether they should be reined in by tools such as competition law to increase access to medicine, education, and innovation, was debated this week at the World Trade Organization committee on intellectual property. Also on the agenda was a suggestion by least-developed countries to create incentives for developed country companies and institutions to transfer technologies for the benefit of the poorest countries.
EU Files WTO Case Against China Over IP Rights Protection 06/06/2018 by William New, Intellectual Property Watch 2 Comments The European Union has filed a World Trade Organization dispute settlement complaint against China for unfair treatment of foreign intellectual property rights holders. The case follows a similar filing by the United States against China.
EUIPO Study Looks At State Of IPR Infringement In The EU 06/06/2018 by Monika Ermert for Intellectual Property Watch Leave a Comment A report published today by the EU Intellectual Property Office (EUIPO) deplores rising volume of intellectual property rights infringement in both immaterial goods and digital content and warns against the economic effects for the Union.
Experts In Geneva: Substandard, Falsified Medicines Not About IP 06/06/2018 by Catherine Saez, Intellectual Property Watch 1 Comment Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization.
Terminando con el acceso no autorizado a los recursos genéticos (biopiratería): Apertura delimitada 06/06/2018 by Intellectual Property Watch 1 Comment El “acceso a los recursos genéticos” y “la participación justa y equitativa de los beneficios que provienen de su utilización” han atribulado las trece Conferencias de las Partes del Convenio de las Naciones Unidas sobre la Diversidad Biológica(CDB), que entró en vigor en 1993. La expresión entre comillas se conoce por sus siglas en inglés como “ABS”. Es el tercer objetivo del Convenio, entrelazado con los primeros dos, que son la conservación y el uso sostenible. A pesar de 25 años de esfuerzos y una bioeconomía de casi un trillón de dólares, pocos son los contratos de acceso que han sido celebrados. De esos pocos, los beneficios monetarios son tan bajos que las partes contratantes (y otros actores) son reacias a divulgarlos, bajo la excusa de “confidencialidad por sensibilidades comerciales”. La ley brasileña de ABS de 2015, que entró en vigor el 6 de noviembre de 2017 por ejemplo, permite que las regalías de las ventas netas sean tan bajas como la décima parte de uno por ciento. En palabras de un erudito jurista, los Usuarios pagan “una miseria por la biodiversidad”.
WIPO Edges Toward High-Level Meeting To Finish Treaty On IP Rights For Broadcasters 04/06/2018 by William New, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization copyright committee last week stepped back from a lunge toward a long-debated treaty to protect intellectual property rights of broadcasters, but still concluded with a recommendation for the full WIPO membership to consider taking the negotiation to the final political level later this year.
New South African IP Policy Text Now Available 31/05/2018 by Intellectual Property Watch Leave a Comment The new Intellectual Property Policy of South Africa has now been posted to a government website.
Fake Medicines To Be Discussed On Side Of WTO TRIPS Council Next Week 29/05/2018 by Intellectual Property Watch Leave a Comment Alongside next week’s World Trade Organization intellectual property committee meeting, Brazil, India, and South Africa are convening a workshop on the neighbouring World Health Organization’s approach to substandard and falsified medicines.